Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brunet, P.
Right arrow Articles by Berland, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunet, P.
Right arrow Articles by Berland, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1994) 9: 650-654
© 1994 European Renal Association-European Dialysis and Transplant Association

research-article

Plasma endothelin in haemodialysis patients treated with recombinant human erythropoietin

P. Brunet1, A. M. Lorec2, F. Leonetti1, C. Roubicek1, K. Jaber1, F. Roux2 and Y. Berland1,

1Service de Néphrologie, Hôpital Sainte-Marguerite Marseille, France 2Laboratoire de Radioanalyse, Hôpital de la Conception Marseille, France

Correspondence and offprint requests to: Correspondence and offprint requests to: Pr Y. Berland, Service de Nephrologie, Hôpital Sainte-Marguerite, 270 Bd de Sainte Marguerite, 13009 Marseille, France

Predialysis plasma endothelin (ET) values were followed during the first 8 weeks of rHuEpo treatment in 12 patients on routine haemodialysis. Mean plasma ET was significantly increased in uraemic patients before rHuEpo (27.9{gamma}11.4 pmol/1), as compared to 40 healthy controls (16.5{gamma}5.7 pmol/1) (p<0.0001). Under rHuEpo treatment, predialysis values remained unchanged although diastolic blood pressure increased after 2 and 6 weeks. We found no correlation between ET and haemoglobin or blood pressure before or under rHuEpo treatment. These results confirmed the high levels of plasma ET in haemodialysis patients, but no increase was observed during rHuEpo treatment.

Keywords: endothelin; haemodialysis; hypertension; rHuEpo; uraemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
K. J Smith, A. J Bleyer, W. C Little, and D. C Sane
The cardiovascular effects of erythropoietin
Cardiovasc Res, September 1, 2003; 59(3): 538 - 548.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.